<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

Vivorté Cites BioMedGPS in the FORTERA and REGENTO bone grafting solutions Release

10/20/17 9:01 AM

Vivorte.pngVivorté, Inc., a vertically-integrated, specialty orthopedic biomaterials company, announced the commercial availability of a complete line of bone grafting product solutions.

Citing BioMedGPS SmartTRAK, Vivorté, Inc. wrote "According to BioMedGPS, the current market for bone graft substitute products exceeds $1.7B annually in the United States alone." Read the Release: "Vivorté announces the commercial availability of FORTERA and REGENTO bone grafting solutions for orthopedic surgery" 

 Subscribe Now for SmartTRAK Blog News Email


Topics: Orthopedics

Sharon O'Reilly
Written by Sharon O'Reilly

Founder, President and Chief Executive Officer Founder, former President & CEO, Medtech Insight, 25+ years' experience in the Medical Device industry in Sales, Marketing, Business Development, Consulting with major manufacturers (J&J, Pfizer, US Surgical), start-up companies and business intelligence providers (Medical Data International, Windhover Information)

    Recent Articles